Asilikang Signs $1.86 Billion AI Drug Research Deal With Insitro; Penghua STAR Market Pharmaceutical ETF Rises 2.26%
2026-10-16 · 3 min read · AlphaGBM
At a glance
The report said Asilikang signed a $1.86 billion artificial-intelligence drug research agreement with Insitro on October 15, aimed at identifying new treatments for liver and heart diseases. As of 10:12 on October 16, 2026, the Penghua STAR Market Pharmaceutical ETF was up 2.26%, while constituent BeOne Medicines had risen 7.50%. The fund tracks the SSE STAR Market Biomedicine Index, which comprises 50 securities from biomedicine and related sectors listed on the STAR Market.
Summary
The report said Asilikang signed a $1.86 billion artificial-intelligence drug research agreement with Insitro on October 15, aimed at identifying new treatments for liver and heart diseases. As of 10:12 on October 16, 2026, the Penghua STAR Market Pharmaceutical ETF was up 2.26%, while constituent BeOne Medicines had risen 7.50%. The fund tracks the SSE STAR Market Biomedicine Index, which comprises 50 securities from biomedicine and related sectors listed on the STAR Market.